Vascular Biogenics Ltd (VBLT)

[Mjmillions]

Why I think VBL is worth over a billion dollars:

VBL overview

As of 03/25/2015, click for up to date information from WSJ:
Market Cap $111.14 M Shares Outstanding 19.90 M Public Float 8.17 M.

VBLT's current PT as of 03/25/2015 is $11.5 from WSJ. Click for latest

Q. Why is VB-111's novel gene-therapy targeting system is so unique and valuable?

A. VBL's patented gene targeting system only targets blood vessels that feed the tumors; meaning no collateral damage or side effects as with nonspecific vectors and chemotherapies.

Q. Why VBL's novel technology is worth over a billion dollars?

A. It's an efficient, no side effects cancer drug. It has no side effects as associated with nonspecific treatments such as chemotherapy. VBL's patented and unique gene-therapy targeting system attacks and kills only the blood vessels feeding the cancer.

watch video

Q. What is VBL developing now and at what stage of development are they?


VB-111 for Glioblastoma (rGBM)--a brain cancer that affects 10,000 people/year newly diagnosed people in the USA--has FDA Fast Track Designation that will make VB-111 available earlier to patients. VB-111 is intending to begin Phase-III pivotal trial mid-2015. Future hope: VBL will have exclusivity for VB-111 until 2027 in the USA and Europe if approved for marketing, which VBL believes is highly likely given its Orphan Drug Designation along with patents already granted.

As of February 1, 2015, we had studied VB-111 in over 166 patients and have observed it to be well-tolerated. We have been granted composition of matter patents that we believe, together with orphan drug designations in both the United States and Europe will provide exclusivity for VB-111, if approved for marketing, until at least 2027.

vblrx.com

NEWS 03/25/2015
VBL Therapeutics' lead drug candidate successful in brain cancer study; shares up 18% premarket

535,000 people are currently living with thyroid cancer, with 60,000 people/year being diagnosed. Thyroid cancer kills about 1,850 people/year.

There were approximately 22,000 American women diagnosed with ovarian cancer in 2013.

Q. Why VB-111's Orphan Drug designation both in the USA and Europe is significant?

A. It's financially more efficient and timely.



NEWS 03/25/2015
Vascular Biogenics beats by $0.10